David Liu

23.3k total citations · 6 hit papers
148 papers, 8.0k citations indexed

About

David Liu is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, David Liu has authored 148 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Molecular Biology, 51 papers in Oncology and 29 papers in Cancer Research. Recurrent topics in David Liu's work include Cancer Immunotherapy and Biomarkers (22 papers), Cancer Genomics and Diagnostics (18 papers) and CAR-T cell therapy research (18 papers). David Liu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), Cancer Genomics and Diagnostics (18 papers) and CAR-T cell therapy research (18 papers). David Liu collaborates with scholars based in United States, Germany and China. David Liu's co-authors include Michael Baseler, Da Wei Huang, Yongjian Guo, Brad T. Sherman, H. Clifford Lane, Richard A. Lempicki, Liliana Ossowski, David Bryant, Robert M. Stephens and Andrew V. Anzalone and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

David Liu

135 papers receiving 7.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists

2007 1.7k citations David Liu et al. profile →
Engineered pegRNAs improve prime editing efficiency

2021 463 citations James W. Nelson, Peyton B. Randolph et al. Nature Biotechnology profile →
Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing

2021 376 citations Andrew V. Anzalone, David Liu et al. Nature Biotechnology profile →
Adopt a moratorium on heritable genome editing

2019 251 citations David Liu et al. profile →
Biologically informed deep neural network for prostate cancer discovery

2021 239 citations David Liu, Saud H. AlDubayan et al. profile →
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours

2024 112 citations David Liu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Liu United States	38	4.4k	1.5k	1.4k	893	813	148	8.0k
Fan Bai China	44	3.6k 0.8×	1.1k 0.7×	1.3k 0.9×	566 0.6×	900 1.1×	177	6.9k
Paolo Fortina United States	47	4.7k 1.1×	1.4k 0.9×	1.9k 1.3×	576 0.6×	875 1.1×	208	9.2k
Stefan Wiemann Germany	51	5.8k 1.3×	1.2k 0.8×	2.1k 1.4×	778 0.9×	753 0.9×	186	8.8k
Alexander D. Borowsky United States	51	4.7k 1.1×	2.6k 1.7×	1.6k 1.1×	1.1k 1.3×	663 0.8×	197	8.7k
Carlos S. Moreno United States	50	4.1k 0.9×	1.3k 0.9×	1.6k 1.1×	1.3k 1.4×	685 0.8×	146	7.3k
Mitchell Stark Australia	27	5.1k 1.2×	1.2k 0.8×	1.3k 0.9×	716 0.8×	754 0.9×	65	7.5k
Dan Mercola United States	55	6.0k 1.4×	2.0k 1.3×	1.4k 1.0×	865 1.0×	755 0.9×	130	8.4k
Anthony D. Whetton United Kingdom	52	5.2k 1.2×	1.4k 0.9×	1.0k 0.7×	1.2k 1.4×	460 0.6×	277	8.9k
Connie R. Jiménez Netherlands	56	4.8k 1.1×	1.3k 0.9×	1.4k 0.9×	655 0.7×	536 0.7×	240	8.6k
Jiang Qian United States	61	7.9k 1.8×	1.2k 0.8×	1.2k 0.8×	805 0.9×	880 1.1×	300	12.4k

Countries citing papers authored by David Liu

Since Specialization

Citations

This map shows the geographic impact of David Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Liu more than expected).

Fields of papers citing papers by David Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Liu. The network helps show where David Liu may publish in the future.

Co-authorship network of co-authors of David Liu

This figure shows the co-authorship network connecting the top 25 collaborators of David Liu. A scholar is included among the top collaborators of David Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Liu. David Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Daliri, Karim, Jürgen Hescheler, Gregory A. Newby, et al.. (2025). Modulating Collagen I Expression in Fibroblasts by CRISPR-Cas9 Base Editing of the Collagen 1A1 Promoter. International Journal of Molecular Sciences. 26(7). 3041–3041. 3 indexed citations

Wan, Guihong, Zoltan Maliga, Tuulia Vallius, et al.. (2024). SpatialCells: automated profiling of tumor microenvironments with spatially resolved multiplexed single-cell data. Briefings in Bioinformatics. 25(3). 2 indexed citations

Liu, David, et al.. (2024). Preoperative 18F-FDG PET/CT in Patients with Presumed Localized Colon Cancer: A Prospective Study with Long-Term Follow-Up. Cancers. 16(1). 233–233. 2 indexed citations

Buchbinder, Elizabeth I., Justine V. Cohen, Giuseppe Tarantino, et al.. (2024). A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma. Cancer Research Communications. 4(5). 1321–1327. 7 indexed citations

Kosnopfel, Corinna, D. S. Faber, Andreas Schlösser, et al.. (2024). Loss of p14 diminishes immunogenicity in melanoma via non‐canonical Wnt signaling by reducing the peptide surface density. Molecular Oncology. 18(10). 2449–2470. 1 indexed citations

Giobbie‐Hurder, Anita, Miklos C. Fogarasi, Patrick A. Ott, et al.. (2024). Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab. Journal for ImmunoTherapy of Cancer. 12(8). e009061–e009061. 5 indexed citations

Sharkey, Aidan, et al.. (2024). Aortic Valve Replacement. JACC Case Reports. 29(8). 102278–102278.

Khaddour, Karam, Rizwan Haq, Elizabeth I. Buchbinder, et al.. (2024). Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma. The Oncologist. 30(3).

Gerstung, Moritz, David Liu, Marzyeh Ghassemi, et al.. (2024). Artificial intelligence. Cancer Cell. 42(6). 915–918. 6 indexed citations

10.

Łaczmański, Łukasz, et al.. (2023). P07 Optimizing DNA specificity and applicability of base and prime editors on COL7A1 variants causing recessive dystrophic epidermolysis bullosa. British Journal of Dermatology. 189(1). e16–e17. 1 indexed citations

11.

Menéndez, David, et al.. (2022). Like mother, like daughter: Adults’ judgments about genetic inheritance.. Journal of Experimental Psychology Applied. 29(1). 63–77. 3 indexed citations

12.

Cheng, Michael L., Jessica Lee, Rachit Kumar, et al.. (2022). Response to MEK Inhibitor Therapy inMAP2K1(MEK1) K57N Non–Small-Cell Lung Cancer and Genomic Landscape ofMAP2K1Mutations in Non–Small-Cell Lung Cancer. JCO Precision Oncology. 6(6). e2200382–e2200382. 4 indexed citations

13.

Nelson, James W., Peyton B. Randolph, Simon P. Shen, et al.. (2021). Engineered pegRNAs improve prime editing efficiency. Nature Biotechnology. 40(3). 402–410. 463 indexed citations breakdown →

14.

Gurjao, Carino, David Liu, Matan Hofree, et al.. (2019). Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair–Deficient Colorectal Cancer. Cancer Immunology Research. 7(8). 1230–1236. 60 indexed citations

15.

Kamran, Sophia C., Jochen K. Lennerz, Claire A. Margolis, et al.. (2019). Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clinical Cancer Research. 25(18). 5561–5571. 62 indexed citations

16.

Schwartzberg, Lee S., Edward S. Kim, David Liu, & Deborah Schrag. (2017). Precision Oncology: Who, How, What, When, and When Not?. American Society of Clinical Oncology Educational Book. 37(37). 160–169. 166 indexed citations

17.

Bourne, Gregory T., Li Zhao, Ashok Bhandari, et al.. (2017). Hepcidin Mimetic Ptg-300 for Treatment of Ineffective Erythropoiesis and Iron Overload. American Journal of Hematology. 92(8). 3 indexed citations

18.

Horak, Christine E., Lajos Pusztai, Guan Xing, et al.. (2013). Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer. Clinical Cancer Research. 19(6). 1587–1595. 83 indexed citations

19.

Zhang, Yi, Yan Cheng, Xingcong Ren, et al.. (2012). Dysfunction of Nucleus Accumbens-1 Activates Cellular Senescence and Inhibits Tumor Cell Proliferation and Oncogenesis. Cancer Research. 72(16). 4262–4275. 29 indexed citations

20.

Harlan, John M. & David Liu. (1992). Adhesion : its role in inflammatory disease. 148 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact